Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 19;18(2):1607–1616. doi: 10.3892/ol.2019.10496

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wei et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 7. — miR-362-5p sensitizes gastric carcinoma cells to cisplatin-induced apoptosis. (A) Flow cytometry and (B) western blot analysis results demonstrated an increase in apoptotic rate (%) and the expression of apoptotic markers (caspase-3 and cleaved-PARP), respectively, following 48-h cisplatin treatment (final concentration of 0.8 µg/ml) in SGC7901/DDP cells transfected with miR-362-5p mimic compared with control cells. (C) Flow cytometry and (D) western blotting results indicated significant decreases in apoptotic rate and the expression of apoptotic markers (caspase-3 and cleaved-PARP), respectively, after 48-h cisplatin treatment (final concentration 0.3 µg/ml) in SGC7901 cells treated with miR-362-5p inhibitor compared with control cells. Columns indicate the mean of three independent experiments. *P<0.05; ***P<0.001. AV, annexin V-FITC; miR-362-5p, microRNA-362-5p; NC, negative control; PARP, poly-[ADP-ribose] polymerase; PI, propidium iodide.